This week, Sam Gyimah, the new Science Minister at the Department for Business Energy and Industrial Strategy (BEIS) announced the awarding of the first £70 million of funding from the government’s £146 million medicines manufacturing commitment.
The funding, made available through the Industrial Strategy Challenge Fund (ISCF), will support projects to speed up the manufacturing of innovative medicines and was announced alongside plans to map the UK’s research infrastructure to ensure the UK remains at the cutting edge.
In a speech this week at Imperial College London, Gyimah said he had heard “clear messages” from the research community on its concerns, including the importance of achieving a good result for science from Brexit; the need to improve business-university links and business-led R&D; and the need to improve diversity in the research community.
As the Medicines Manufacturing Industry Partnership (MMIP), we’ve worked closely with the government and Professor Sir John Bell on the Life Sciences Industrial Strategy, securing a total of £146 million of funding for medicines manufacturing throughout the UK.
The allocation of investments made today are the next step in the government delivering our joint vision of a UK is open for business and an attractive destination for medicines development and manufacturing.
Investing in manufacturing centres for complex medicines and packaging technologies has the potential to deliver both economic rewards and health benefits for the UK, speeding up access to innovative and high-quality medicines for patients and the NHS.
To date, the funding of medicines manufacturing made through the ISCF includes:
Another £10 million worth of funding for the second round of the ISCF will be allocated this year, with applications for funding opening on 12 March 2018.